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Cardiac Regeneration
Sara Leah Abraham
Introduction
Cardiovascular disease is a generic term that refers to any illness or disorder that involves
the heart and its vessels or the blood vessels of the body. Cardiovascular disease has been
accepted as the leading cause of death worldwide. According to the Centers for Disease
Control’s National Vital Statistics Reports, twenty six percent of deaths in 2006, 631,636 in
total, were caused by diseases of the heart (Heron et al. 2009).
One of the most common of all cardiovascular diseases is Ischaemic Heart Disease. This
coronary artery disease often leads to Acute Myocardial Infarction, more commonly known as a
heart attack. An ischemia occurs when an organ is receiving an insufficient supply of blood,
often caused by a clogged artery (De Milto 2006). Atherosclerosis and blood clots in some of
the larger coronary arteries are the most common condition to block coronary circulation.
Coronary arteries take rise from the root of the aorta and spread out over the epicardium. These
arteries branch out into energy hungry cardiac muscle, the myocardium, to supply it with oxygen
and nutrients. The blockage of these deep arteries is known as myocardial ischemia. When
ischemia to a specific region is severe, injury occurs (American Heart Association 2008). When
blockage results in cell death, the condition is called an infarction.
Myocardial infarction is characterized by necrosis, cellular death in an isolated region of
the heart. Cellular death stimulates the migration of macrophages to the infarct zone. They
remove the necrotic tissue, and the area is refilled with a dense collagen scar, leading to a
decrease in muscle thickness. The scar tissue, by and large, is acellular, and does not have the
biochemical properties of myocardial cells. This can lead to electrical inconsistencies, loss of
structural integrity, and mechanical dysfunction, such as arrhythmias. Together, these
abnormalities can lead to complete heart failure (Joggerst and Hatzopoulos 2009).
Current treatments for post myocardial infarction patients aim to assist in the healing
process and prevent further heart attacks, such as cholesterol-lowering medications and
angiotensin inhibitors. A rehabilitation plan that includes blood pressure and cholesterol
management may be set up. Diet and exercise regimes may change (Mayo Clinic 2010).
Ultimately, though, once an area of the myocardium is dead, it’s irreversible. It is because of this
that scientists are looking for ways to alleviate the effects of myocardial ischemia and infarction
by means of cardiac regeneration.
Cell Therapy
The basic concept of cell therapy is that exogenous, or possibly even autologous cells
implanted into diseased tissue can recover and improve its function by substituting for the
resident cells that have died. The improved neurologic function of Parkinson’s patients that
underwent the grafting of intracerebral dopaminergic cells and the prospect of weaning a number
of diabetics off insulin after Langerhan islet transplants provide a good indication that cell
therapy can be clinically effective. Transplanted cells must be engrafted in very specific
quantities, and they must be able to integrate into normal host tissue without excess reproduction
19

and other adverse effects. When attempts to ameliorate the effects of myocardial infarction by
converting the infarct zone into contractile tissue with the use of viral vectors encoded with
muscle specific master genes failed, cell therapy became an increasingly attractive method of
attempted cardiac regeneration (Menasche 2004).
Stem Cells:
Stem cells can be defined by two significant characteristics. First and foremost, they
must be able to self-renew. They must be able to go through many cycles of mitosis and still
remain in their undifferentiated state. Secondly, a stem cell must have the capability to
differentiate into various specialized cell types. The effectiveness and value of stem cells are
often based on their potential to do this. Pluripotent stem cells are able to differentiate into
specialized mature cells from the three germ layers. The embryonic stem cell is the classic
example of a pluripotent stem cell. Multipotent stem cells, alternatively, are limited to
differentiating into mature cells of directly related lineages, generally from the same germ layer.
Adult stem cells, sometimes called somatic stem cells, that are derived from postnatal, or even
fully mature tissue are generally multipotent. Some adult stem cells sometimes have a more
limited capacity for self-renewal, and are committed to differentiation into specific lineages.
These cells are called adult progenitor cells (Cook et al. 2009). Until very recently, the
myocardium has been labeled and viewed as an end-differentiated organ – one without any
potential for regeneration. Certain types of stem cells are currently being tested as sources for
regenerative potential for the heart. There is a new availability for hope in the possibility of
reconstructing the infracted, failing ventricle (Loscalzo et al. 2008).
Mesenchymal Stem Cells:
Mesenchymal stem cells (MSCs) were first identified by their ability to form fibroblast
like populations, and have been recognized for their plasticity. In the past, they have been
known to help normal bone regenerate in vivo. They were initially discovered in the stroma of
bone marrow. It has been established that by secreting growth factors important for proliferation
and colony stimulating factors, MSCs provide support for hematopoiesis. While generally
harvested from bone marrow, MSCs have recently been found in and isolated from the placenta,
adipose tissue, the liver, and umbilical cord blood. MSCs, an integral part of the composition of
endothelium (perivascular cells), are now seen as ubiquitous. No single, specific marker for
MSCs has been discovered yet, though they are characteristically lacking typical hematopoietic
antigens, such as CD 34, CD 44 an45, and more. MSCs produce a large number of cytokines
and growth factors, including the important vascular endothelial growth factor . The hallmark
and most distinctive feature of the mesenchymal stem cell is its inherent ability to differentiate
into anything of mesodermal lineage, such as bone, cartilage, tendon, muscle, and adipose tissue.
The main advantage of MSCs in cell therapy is their unique immunological properties. They can
be transplanted across major histocompatibility barriers; recipients will not need to take
immunosuppressants. They can be taken from any healthy donor, even an unrelated one, and
cryopreserved until needed. With their ability to self-renew and differentiate, MSCs can be
induced to differentiate into cardiomyocytes, and there is evidence that MSCs migrate primarily
to sites of inflammation. These factors together suggest their potential for treatment for ischemic
myocardial infarction. A disadvantage of MSCs is that they are perhaps too heterogenic, and
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there are concerns that they may provide unexpected results, such as ossification (Cook et al.
2009).
Intracoronary injections of autologous bone marrow have led to moderate recovery of
cardiac function, but clinical findings show that bone marrow cells don’t actually engraft in the
infarct zone, nor do they reduce infarct size. A placebo controlled study was therefore done to
increase the evidence that MSCs have reparative properties. To ensure that mesenchymal stem
cell grafts were allogeneic, donor pigs were of a different strain than recipient pigs. The bone
marrow was obtained from the iliac crests of male swine. MSCs were identified and isolated by
density, and were plated to expand in culture, and were then cryopreserved. They were
magnetically stained in order to be later identified under MRI. Recipient pigs underwent a
surgically induced myocardial infarction via balloon occlusion of the left anterior descending
coronary artery for sixty minutes, followed by reperfusion; left ventricular performance and
cardiac oxygen consumption was measured. After three days, animals were randomly chosen to
receive intramyocardial infusions of allogeneic porcine MSCs or a placebo through a needle
tipped injection catheter. Contractility of the myocardium was measured by the maximal rate of
isovolumetric contraction and ventricular elastance, and the ratio of left ventricular systolic
pressure to stroke dimension. At day three post injection, no animal had died or shown signs of
arrhythmias, or shown signs of cardiac perforation, thus indicating that the method of delivery
was safe. The animals were euthanized after eight weeks. Their hearts were analyzed in gross
and microscopic levels. Tissue samples were taken from the infarct zone, the infarct border, and
remote tissue. Immunostaining revealed the presence of α-actinin, troponin-T, and myosin heavy
chains. Histologic evaluation demonstrated that MSCs were found present throughout the infarct
and border regions, and they expressed muscle specific proteins that weren’t found while they
were still in culture plates. They were also found in vascular structures, where they had
incorporated into vascular smooth muscle and endothelium. Myocardial infarction normally
begins at the subendocardial area of the myocardium and moves out through the midmyocardium
out towards the subepicardia
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region. In animals that received a mesenchymal stem cell transplant, the infarct region was
confined to the midmyocardium. When measured, the subendocardial rim was thicker in the
mesenchymal stem cell-treated group than in control groups. MSCs probably caused this
cardiac regeneration of the subendocardium. The effects of the transplant on cardiac function are
as follows (see table 1).
The animals exhibited recovery to almost normal levels of both systolic and diastolic function.
Myocardial efficiency increased, almost bringing stroke work back to a normal level. Cardiac
energy metabolism was nearly recovered (Amado et al 2005).
Hematopoietic Progenitor Cells /Bone Marrow Mononuclear Cells:
Hematopoietic progenitor cells are the only stem or progenitor cell that are routine in
clinical use today, due in part to the fact that they are easy to isolate and feasible to implant
(Joggerst and Hatzopoulos 2009). They reside in bone marrow, and are responsible for making
all blood cells, constantly repopulating the hematopoietic and immune systems. They are used in
bone marrow transplants to treat many disorders, including leukemia and aplastic anemia. In
humans, hematopoietic progenitor cells are identified by the CD 34 marker (a surface
gylocoprotein). Hematopoietic progenitor cells home to bone marrow in healthy mammals,
where they adhere firmly to the endothelium. Whether or not hematopoietic progenitor cells
actively participate in the repair of cardiomyocytes after an infarction is a matter of debate,
though they have been known to differentiate into skeletal muscle fibers. It is generally
accepted, though, that hematopoietic progenitor cells are responsible for the inflammatory
wound healing process (Cook et al. 2009). Experimental studies have suggested that
intramyocardial or intravascular administration of bone marrow derived hematopoietic
(Amado et al. 2005)
progenitor cells may play a part in the functional regeneration of infarcted cardiac muscle by
enhancing neovasculogenesis of an ischemic myocardium (Schachinger et al. 2006).
Patients, aged eighteen to eighty, were eligible for the REPAIR-AMI (Reinfusion of
Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial if they’d
had an ST-elevation myocardial infarction with residual left ventricular wall motion abnormality
and a significantly decreased left ventricular ejection fraction (Schachinger et al. 2006). (A
normal resting ejection fraction, the fraction of blood pushed out of the heart by the ventricles
per beat, is 62.3±6.1% [Pfisterer and Battler 1985].) This placebo controlled, double blind
randomized trial was performed in seventeen different centers, at a median of 4 days after AMI
reperfusion therapy. Bone marrow biopsies were done on 204 patients and the aspirate was sent
to a single cell-processing laboratory, where patients were randomized to receive either an
intravascular infusion of bone marrow derived hematopoietic progenitor cells (101 patients) or a
placebo medium (103 patients). This infusion was done using a stop-flow technique via balloon
positioned in the infarct-related coronary artery. After four months, the BMC (bone marrow
cells, and alternate name for hematopoietic progenitor cells) group showed enhanced contractile
recovery of left ventricular function. One year later, the results of the experiment were
measured. A total of eight deaths occurred in the year, six in the placebo group and 2 in the
BMC group. None of the patients in the BMC group experienced a second myocardial
infarction, while six patients in the placebo group suffered a total of eight myocardial infarctions,
six of which were located to the target blood vessel. While on paper these numbers may seem
small, statistically, the difference is significant. Similarly, additional revascularization
procedures were needed less frequently in the BMC group than in the placebo group. Thirty22

eight revascularizations were needed in thirty seven patients of the placebo group, while only
twenty five were needed in twenty two patients of the BMC group (Schachinger et al. 2006).
The BMC group can be seen as a predictor of a reduced cardiovascular event rate. It is
reassuring that in every endpoint, be it death, another myocardial infarction, or rehospitalization
due to heart failure, there was a trend, albeit a statistically insignificant one, in favor of the BMC
group. This data suggests that the contractile recovery seen at four months may possibly
translate into a better clinical outcome one year post BMC infusion (Schachinger et al. 2006).
Cardiac Stem Cells:
The steps that have been made towards cardiac regeneration through the various stem cell
types prompted further research into any natural regenerative properties and mechanisms that
cardiac tissue might have. The heart has always been viewed as a postmitotic organ because
mature cardiomyocytes don’t reproduce or propagate. Contradictory facts seemed to accumulate
as cardiomyocytes were discovered proliferating and reentering the cell cycle in certain
pathological conditions such as ischemia and hypertension (Joggerst and Hatzopoulos
2009). After a female heart was transplanted into a man, male cardiomyocytes and endothelial
cells were found growing within the heart. Y-chromosome positive cells must have migrated
from the recipient’s atrial stump or bone marrow into the donated heart, and differentiated into

23

(Schachinger et al. 2006)

functional cardiomyocytes (Quaini et al. 2002). Since then, several types of cells have been
discovered in the adult heart that have stem cell characteristics. One stem cell characteristic is a
cytoplasmic exclusion of certain vital dyes, like Hoechst 33342 and Rhodamine
123. Populations of these cells, sometimes called side population cells, have been found in
various organs, such as skeletal muscle, bone marrow, and adipose tissue. These cells have
recently been found in cardiac tissue as well, concentrated in the deep tissue of atria and
apex. Cardiac side population cells have been seen to differentiate into cardiomyocytes,
suggesting that they may in fact be cardiac progenitor cells. After cardiac injury, such as
ischemia, these cardiac side population cells are mobilized and move to the injury site. The
apparent conflict between the existence of cardiac progenitor cells and the heart’s lack of
regenerative ability is still puzzling to researchers, though two theories have been developed.
The first is that these cells, along with mature cardiomyocytes, cannot survive the hypoxic
conditions of ischemia. The second is that the pool of cardiac stem cells diminishes with age,
which can possibly contribute to lack of regeneration in the elderly (Joggerst and Hatzopoulos
2009).
Studies have found what have been loosely termed human cardiac stem cells in small
niches in the heart. These small clusters of human cardiac stem cells are closely connected to
myocytes and fibroblasts by gap junctions and adherans junctions. The myocytes and fibroblasts
form supporting walls that contain the cardiac stem cells. These cells are very obviously
committed to myocyte lineage. Stem cell antigen C-kitPOS, sarcomeric proteins, and myocyte
transcription factors are co-expressed consistently, though they sometimes also expressed
transcription factors for endothelial cells and smooth muscle cells. Myocardial samples were
enzymatically dissociated, and C-kitPOS cells sorted out and plated; multicellular clones were
formed successfully in eight out of twelve cases. These clones were, in turn, plated again, or
placed in individual wells. Doubling time was approximated at 29 hours. These cells
differentiated into cardiomyocytes, smooth muscle cells, and endothelial cells. Developing
myocytes had sarcomeric units, were striated, and showed contractile activity after electrical
stimulation (Bearzi and Rota 2007).
Human cardiac stem cells were collected from eight patients and injected into infarcted
mouse or rat heart, forming chimeric organs that contained human myocytes and coronary
vessels. Cell therapy led to regeneration in the infarct zone. The new cells tested positive for αsarcomeric actin and human DNA sequences were found in seventeen out of twenty five treated
mice and fourteen out of nineteen rats. Of the new tissue, ≈84% was myocardial and ≈8%
consisted of new microvasculature, making an approximate ration of one capillary to eight
cardiomyocytes. Two different lentiviruses were injected into the cardiac stem cells and the
infarcted rat and mice hearts to promote different dye production, and the results showed that
there had been no cell fusion. The new cardiomyocytes were all human, and that animal
cardiomyocytes did not contribute to the regeneration or repair. An examination of ECG done
on injected hearts showed that tissue regeneration had partially restored contractile function in
the infarct, resulting in an increased ejection fraction and a general improvement of ventricular
function. When examined, the synchronicity of calcium tracings in both human and rat
cardiomyocytes proved their functional integration. An occasional protein was even found
linking human and rodent cardiomyocytes. Together, these observations all prove the role of
transplanted human cardiac stem cells in cardiac homeostasis and myocardial regeneration
(Bearzi and Rota 2007).
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Skeletal Myoblasts:
While the regenerative ability of cardiac muscle cells is a relatively new development, it
has been known for a while that skeletal myoblasts retain the potential to regenerate. This is due
in large part to the presence of stem cells, sometimes called satellite cells, in this case, because of
their location in the periphery of mature, multinucleated muscle tubules. A billion or more
myoblasts can be easily cultured in the laboratory from a single small piece of muscle tissue.
Myoblast therapy was developed originally as a possible treatment for muscular dystrophy,
because myoblasts from a normal donor would fuse with the muscle of the recipient to provide
normal proteins absent from dystrophic patient. In 1992, scientists realized the potential use of
skeletal myoblasts in cardiac regeneration. Over time, experiments proved that myoblast
transplantation could repair a damaged myocardium when cells engraft and integrate, adding
new contractile muscle to the heart, and by promoting cardiac repair, including rejuvenation of
blood supply, and therefore oxygen and nutrients, to previously damaged areas (Dinsmore and
Nabil 2006).

25

Of one the wonderful things about myoblast therapy is that it can be autologus. In
preparation for transplant, a skeletal muscle biopsy about five grams is done. The muscle is
trimmed of all connective tissue and minced. It then goes through several cycles of digestion
with trypsin and collagenase. The resulting cells are plated and grown in a medium developed
primarily for supporting myoblast growth. The actual number of cells used for transplant can be
anywhere from three hundred million to eight hundred million. Animal studies done with
transplantation of skeletal myoblasts into ischemically damaged myocardium have demonstrated
good results. They show that skeletal myoblasts engraft and contribute to improved heart
function; they have survived long term without manifesting adverse affects, such as arrhythmias.
Autologus rat myoblasts grafted into ischemic myocardium survived both inside and out of the
infarct zone, and fused, forming myotubes in close contact with myocytes at the border of the
infarct zone. Myocardial contractility and cardiac output increased in comparison to the control
group. Ventricular volume and remodeling were minimal. In sheep, progressive heart failure
halted short term , and was functionally reversed in the long term. Skeletal muscle fibers formed
organized bundles that co-aligned with adjoining cardiac muscle. Muscle density in areas of
ischemic collagen scars was almost restored to normal. Clinical studies have been done in both
the USA and Europe, and direct evidence for skeletal myoblast survival had been provided.
Autologus myoblasts formed myofibers that survived in the human myocardium and aligned

Autologous human myoblast transplantation in a
human patient as an adjunct to coronary artery
bypass surgery on a beating heart (Haider et al.
2004).
parallel to host cardiac muscle fibers, showing potential for synchronized contraction. This in
turn, can contribute to improvements in systolic and diastolic functioning. Left ventricular
ejection fraction increased. Tissue viability scanning of the scarred region of the myocardium
six months post transplant showed improved metabolic activity (Dinsmore and Nabil 2006).
While the theory shows great promise, a few problems with myoblast transplantation were
exhibited in some trials. Ten patients that received myoblast transplants reported severe left
ventricular dysfunction. Their ejection fraction dropped significantly to below 35%. In the
MAGIC (Myoblast Autologuous Grafting in Ischemic Cardiomyopathy) trial, four out of sixty
four patients developed ventricular tachycardia after receiving skeletal myoblast injections in
coronary artery bypass grafting, and twenty four more were expected to. Therefore, clinicians
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must proceed with caution in regard to arrhythmias in pursuing myoblast therapy. Furthermore,
many myocardial infarction patients are not surgical candidates, and a less invasive method of
delivery must be devised (Dinsmore and Nabil 2006).
Of all the various studies done to investigate the effects of cell therapy on myocardial
infarction, few have taken timing into account, and as of yet, the optimal time for cell
transplantation in heart attack patients remains unclear. One such study was done in 2009 using
human umbilical cord blood cells (HUCBC), which are rich in mesenchymal progenitor cells and
contain endothelial cell precursors with huge in vitro proliferation capabilities. Myocardial
infarction was identified in eighty male Wistar rats by elevated ST segments in a transthoracic
ECG. Equal volumes of either HUCBCs or a phosphate buffered saline placebo were injected
into the rats through a caudal vein at days one, five, ten, and thirty after myocardial infarction.
The rats were all sacrificed four weeks post infusion, after a hemodynamic assessment and an
ECG. Mortality in rats transfused on day one post infarction was 40%, most deaths occurring
within one week. Rats infused on day five and day ten both hard mortality rates of 10%, and
those injected thirty days after the myocardial infarction had a mortality rate of 30%, usually at
three weeks post infarction. Before injection, all rats had a similar left ventricular ejection
fraction of about 45%. After four weeks, the left ventricular ejection fraction in five-day
transplantation group had moved up to about 50% and the ten-day group reached almost 60%,
doing significantly better than the control groups. Left ventricle wall thickening also improved
significantly in the 10-day group, as opposed to the others. While scar formation was extremely
noticeable in hearts injected with buffered solution, scar size was smaller in groups that received
the HUCBC injection, more so in the five and ten day groups than the others. When injected
cells were immunostained with anti-human leukocyte antigen, it was observed that only cells
delivered in the ten-day group had settled in the infarct zone in the myocardium enough to make
a difference. New angiogensis was due to the endothelial progenitors found in HUCBC.
Microvasculature density was significantly greater in the five-day and ten-day groups than in
their controls, and was altogether greater in the ten-day group. Myocardial infarction is a time
dependent process, based on the loss of effective cardiomyocytes and the formation of scar
tissue. The process begins with an inflammation of the infarct zone, and this reaction is nearly
complete at ten days post myocardial infarction. It can be concluded that this is the best
environment for stem cell homing and survival (Xing, Yun-li et al. 2009).
Tissue Engineering
Cardiac muscle tissue has a very quick and active metabolism. It therefore requires a lot
of oxygen and nutrition. In natural cardiac tissue, almost every cardiomyocyte can be found in
close proximity to a capillary vessel, ensuring that each cell is properly perfused and taken care
of. Cardiac cell density is much higher than most other tissues. In a normal heart, noncardiomyocyte cells such as vascular endothelial cells, smooth muscle cells, and fibroblasts make
up 70% of the tissue. These non-cardiac cells are integral to normal heart functioning. All these
factors together make it very difficult to artificially create cardiac muscle (Guo et al. 2009).
One study investigated the effects of co-seeding rat mesenchymal stem cells with
embryonic cardiomyocytes. The scientists conducting the study believed that the only way to
attempt to engineer cardiac muscle is in three dimensions, so they constructed a three
dimensional tubular scaffold called a myotubule. They fed liquid collagen between two rotating
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cones, resulting in a cylindrical tube of collagen fibrils with a hollow, inner central lumen. To
isolate the mesenchymal stem cells, they anesthetized 300 rats and removed the femoral and
tibial bones. The marrow cavities were flushed and the marrow was combined. The bone
marrow was passed through thin needles to break up clumps, and the single cell suspensions that
resulted were centrifuged for five minutes at 200g. Cells were trypsinized three times, and
replated. Only bone marrow stromal cells remained. Cells were labeled with green fluorescent
protein for lineage tracing, and were replated for subculturing. Embryonic cardiac myocytes
were collected from rat embryos. Upon the dissection of their hearts, the atria were discarded.
The ventricles were minced and incubated, and centrifuged, until ventricular primary cells could
be isolated. The embryonic ventricular cardiomyocytes (ECMs) were planted in a medium
filled collagen tube alone, and a combination of ECMs were seeded together with mesenchymal
stem cells. The results of both experiments were studied at seven, fourteen, twenty one, and
twenty eight days. Gene expression of the tissue in both myotubules was studied in order to
analyze cardiogenic differentiation. In order to validate findings of cardiac myocyte markers in
these collagen tube cultures, cardiac specific markers were immunocytochemically stained. This
was done using antibodies directed against specific cardiac transcription factors, hormones,
contractile and structural filaments, and junctional proteins. Through staining and lasers, it was
established that the cells located in the myotubes tested positive for many cardiomyocyte
markers, including myosin heavy chains, sarcomeric myosin heavy chains (a contractile protein),
cardiac troponin, cardiac actinin and desmin, GATA binding proteins, peptide hormones ANP
and BNP, and others (Valarmathi et al. 2010).
At 21 days, ECM tube cultures showed the presence of myocytes mainly on the luminal
and outer surfaces of the construct. External to the tubule, ECMs aligned and overlapped in an
orderly manner, but cells on the inner luminal surface showed cord like cellular arrangement that
resembles that of in-vivo myocytes. These cells showed signs of developing sarcomeric units,
and tested positive for actin and myosin. They indicated progressive differentiation towards invivo neonatal-like ventricular cardiac muscle cells. In MSC/ ECM co-cultures, the
differentiating cells appeared organized into many layers of intercalated bundles and branches
throughout the myotubule. Cross bridges and specialized cell junctions were evident. The
maturing cardiomyocytes showed evidence of evolving into Z-disks and into cardiac specific
sarcomeric arrangements, and showed promise for cardiac biosynthetic activities. The MSCs
that had been immunostained showed markers associated with cardiomyocytes, including myosin
heavy chains and other aforementioned characteristic, proving that it wasn’t only the ECMs
affecting the expression of cardiac properties. In comparison to the ECM only construct,
hormone secretion levels of the MSCs/ECMs stayed strong and constant. The cells were
metabolically active. When tested under electron microscope, the nuclei of ECMs were typical
of underdeveloped embryonic cardiac muscle cells. The MSCs/ECMs co-culture revealed the
typical appearance of developing cardiomyocytes. Cells were elongated, multilayered, and
orderly. Myofilaments were present, if randomly dispersed throughout. Plus, the cells showed
developing mitochondria and vescicles of the active cardiomyocyte. MSCs/ECMs combination
expressed cardiac specific genes, proteins, ion channels, receptors. In addition spontaneous,
synchronized contraction of the culture was evident through the transparent myotubule
(Valarmathi et al. 2010).
Previous successes in the implantation of engineered cardiac tissue have failed due to
necrosis at the core of the transplanted tissue and poor survival related to ischemic injury.
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Bioengineers have long sought a solution to this problem. Human embryonic stem cells were
differentiated into cardiomyocytes and suspended in a rotating orbital shaker, resulting in human
cardiac tissue patches, composed of enriched cardiomyocytes. These patches, however, did not
survive transplantation in-vivo. Scientists tried heat shocking the patches a day before
implantation and bathing them in prosurvival cocktail before implanting them into skeletal
muscle of nude rats. At one week, they found only rare, isolated human cardiac muscle cells. The
peripheral edges of the tissue were viable, but the entire inner core was dead. They deduced that
the problem was in large part due to the ischemic injury at the infarct zone, and that the patches
were too thick for nutrients to diffuse into the core, and that in order for the procedure to be
successful, the tissue needed to be vascularized. The tissue patches died before host
angiogenesis could provide them with a normal blood supply (Stevens et al. 2009).
Tri-cell cardiac patches were scientists’ next attempt. Human embryonic stem cell
derived cardiomyocytes were combined with human umbilical vein endothelial cells (HUVEC)
and mouse embryonic fibroblasts in a 1:1:0.5 ratio in a medium of human embryoid bodies (a
cluster of heterogeneous embryonic stem cells that are set to differentiate to a specific lineage
[Itskovitz-Eldor et al. 1999]). The newly created tissue had endothelial cell networks that
resembled a vascular plexus. The next logical step was to test the contractility of the new tissue.
Patches were stimulated using square waves of frequency and contraction was monitored via
video edge detection. Cardio-HUVEC-MEF patches were cultured for 2-3 days before testing.
They routinely contracted when stimulated by 2 Hz of electricity (120 beats/minute), but
couldn’t keep pace with 5 Hz of stimulation. When stimulated at higher frequencies, the patches
never fully relaxed, and a decrease in contractile ability resulted. Another important
consideration for scientists to take into account are the passive mechanical properties of cardiac
tissue, especially in relation to diastolic filling. The passive stiffness of Cardio-HUVEC-MEF
patches were tested in comparison to cardio only patches by using strips cut from each patch.
They were stretched in increasing length increments. At 7.9 mN/mm2, cardio-HUVEC-MEF
constructs were closer to the stiffness of neonatal pig myocardium than cardio-only patches.
When tested, scientists saw that the cardio-HUVEC-MEF constructs produced more connective
tissue and collagen fibrils per area, making their stiffness more physiologically appropriate.
These patches were a thousand times less stiff than the collagen scar that forms as a result of
myocardial infarction, suggesting that they would impede much less on diastolic filling (Stevens
et al 2009).
The next step for scientists was to test whether or not these vascularized human cardiac
tissue patches could survive implantion in vivo. Prior to their implantation into the gluteus
muscle of nude rats, cardio-only and cardio-HUVEC-MEF patches were heat shocked and
bathed in pro-survival cocktail. At one week post implantation, the rats were killed. Human
cardiomyocytes and endothelial cells were indentified through the immunohistochemical staining
of β-myosin heavy chain and human complement proteins. In cardio-only patches, only the
occasional, isolated human cardiomyocytes were detected. Comparably, cardio-HUVEC-MEF
patches formed much larger grafts of human myocardial tissue. The cardiac muscle cells showed
small, sarcomeric arrangements. Many human endothelial cells could be found among the
patches, some of them even containing traces of red blood cells. Despite the fact that cardio-only
patches were produced from 50% more cardiomyocytes, implanted cardio-HUVEC-MEF patches
grew to be 11 times larger. Next, the cardio-HUVEC-MEF constructs were sutured into the
hearts of nude rats. The patches had attached to the hearts of all test subjects. The microvessels
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that had formed contained red blood cells and white blood cells, indicated that the new vessels
had anastomosed with the normal rat blood vessels, creating a much more ideal environment for
tissue survival. (Stevens et al. 2009).
In the ten years that scientists have been experimenting with tissue engineering, much
progress had been made. Nevertheless, there are still many obstacles that need to be overcome
before newly synthesized cardiac tissue can be used to alleviate the effects of myocardial
infarction. One of the largest problems facing bioengineers is constructing tissue the proper size
and shape to fit into human myocardium. So far, no three dimensional tissue construct has been
thick enough or large enough. Three to four cardiomyocyte monolayers have been successfully
stacked one on top of the other, but the thickness hasn’t come close to that of human cardiac
tissue. As for shape, researchers have been able to construct tissue in rings, strips, and squares.
While each of those shapes has its own advantage, none of them come close to the shape of a
natural human heart. Of course, another large issue is immunorejection. None of the methods
developed thus far have used or yielded autologus material. All implantation studies have used
immunosuppressants. Another commonly overlooked problem is that most media supplements
used to grow the tissue are xenogenic, resulting in several issues including infection. New, nonxenogenic growth media must be developed before engineered tissue can successfully be
transplanted into humans (Xing, Yu-jie et al. 2009 b). Until this tissue has been successfully
transplanted, studies cannot be done to test how this tissue affects the functionality of the
working heart.

Conclusion
Because myocardial infarction and the death of cardiac muscle has always been
seen as irreversible, researchers have been working on many different ways to reverse the
process and regenerate cardiac muscle. In most studies, heart function was partially, if not
mostly restored, even if cardiac muscle itself was not actually produced. The reperfusion of
existing muscle and the prevention of scar formation definitely played a part in reestablishing
cardiac function and preventing further heart complications. Researchers discovered the
existence of cardiac progenitor cells and have begun to experiment with them. Tissue has been
engineered and successfully transplanted into rats. Much progress has been made in the field,
though there are still obstacles that need to be overcome. Many studies featured embryonic cells,
the use of which is still extremely controversial, and may lead to tumor formation in the long run
(Joggerst and Hatzopoulos 2009). Finally, more human trials need to be done to prove the safety
and benefits of cell therapy and tissue transplantation.
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